SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Core Viewpoint - SCYNEXIS, Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement for its common stock, allowing until June 15, 2026, to maintain a closing bid price of at least $1.00 per share for ten consecutive business days [1][2]. Company Overview - SCYNEXIS, Inc. is a biotechnology company focused on developing innovative medicines to combat difficult-to-treat and drug-resistant infections [4]. - The company is advancing its proprietary antifungal platform "fungerps," with Ibrexafungerp being the first representative licensed to GSK [4]. - The FDA has approved BREXAFEMME® (ibrexafungerp tablets) for treating vulvovaginal candidiasis (VVC) and reducing recurrent VVC incidence [4]. Strategic Objectives - The company plans to leverage its balance sheet to complete a Phase 1 study of an intravenous formulation for SCY-247 and generate proof-of-concept Phase 2 data for its oral formulation targeting invasive candidiasis infections [3]. - SCY-247 is anticipated to provide benefits for both hospitalized and community patients facing challenging infections, and it is highly regarded within the anti-infective scientific community [3]. Compliance Commitment - SCYNEXIS is committed to regaining compliance with all Nasdaq listing requirements and intends to take necessary actions within the 180-day extension period, including a potential reverse stock split if needed [2][3].